Tag Archives: act

Are 4 Top-Rated IBD 50 Drug Stocks On Your Radar?

The IBD 50 is a ranking of leading stocks based on key fundamental and technical measures including earnings and sales growth, profit margins, return on equity and relative price performance. Here’s a closer look at four drug stocks that made the new list Friday: Regeneron Pharmaceuticals (REGN), Valeant Pharmaceuticals (VRX), Actavis (ACT) and Gilead Sciences (GILD). Regeneron has a highest possible IBD Composite Rating of 99. On Friday, the FDA

Meet 8 Hot Med Stocks Among IBD’s Big Cap Leaders

IBD’s Big Cap Leaders screen filters through highly liquid, large-cap stocks with a strong record of earnings growth. Eight top-notch medical stocks that made the screen’s cut are Valeant Pharmaceuticals (VRX), Gilead Sciences (GILD), Celgene (CELG), Actavis (ACT), Biogen (BIIB), Regeneron (REGN), Shire (SHPG) and Illumina (ILMN). Valeant Pharmaceuticals has a highest-possible IBD Composite Rating of 99, meaning its shares outperform 99% of all

Actavis, Valeant Up On Bowel-Disease Drug Approvals

Specialty-drug giants and IBD 50 stocks Actavis (ACT) and Valeant Pharmaceuticals International (VRX) were both trading up Thursday morning after the FDA approved both of their bowel-disease drugs late Wednesday. Valeant’s Xifaxan 550 and Actavis’ eluxadoline, now branded Viberzi, were both approved for irritable bowel syndrome with diarrhea, or IBS-D. As IBD reported in our summer drug-approval preview, despite this commonality the drugs are